JAZZ News and Press, Jazz Pharmaceuticals plc From 11/20/22

It's been a mostly down year for cannabis stocks. Declining profits for some multi-state operators (MSOs) have soured many investors on the sector, with the ETFMG Alternative Harvest ETF and the AdvisorShares Pure Cannabis ETF down roughly 46% and 58%, respectively, so far this year...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) PR Newswire Rylaze dosing options provide sustained asparaginase activity throughout the en...

Buying stocks right now can seem like a bad idea given that the stock market isn't on firm footing, with the S&P 500 down 16% this year. But the volatility in 2022 can create some attractive buying opportunities for long-term investors. A couple of attractive stocks to buy right...

Summary Jazz Pharmaceuticals reported solid Q3 results and raised the full-year guidance by $50 million at the midpoint. Xywav is overtaking Xyrem as the company's top-selling product, thanks in part to a strong launch in idiopathic hypersomnia. Discontinuation of nabiximols i...

STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING PR Newswire LOS ANGELES , Nov. 14, 2022 /PRNewswire/ -- Stand Up To Cancer ® (SU2C) announced today the launch of a new public service announce...

Summary This week saw quite a bit of volatility, yet the VIX continues to fall. This is telling us that there's a lot of complacency out there. The market welcomed a lower inflation number, that's great, but then it ran up out of all proportion on Friday. I expect this week we...

Jazz Pharmaceuticals plc (JAZZ) Q3 2022 Earnings Conference Call November 09, 2022 04:30 PM ET Company Participants Andrea Flynn - VP and Head, IR Bruce Cozadd - Chairman and CEO Dan Swisher - President Rob Iannone - EVP, Global Head of R&D Renée...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) updated full-year guidance includes an adjusted EPS estimate range that includes the consensus guidance. The company is expecting adjusted EPS of $17.20 to $17.85 (consensus $17.30). It also raised the midpoint of its revenue guidance ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2022 Q3 earnings call. For further details see: Jazz Pharmaceuticals plc 2022 Q3 - Results - Earnings Call Presentation

Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q3 Non-GAAP EPS of $5.17 beats by $0.50 . Revenue of $940.65M (+12.2% Y/Y) in-line. FY2022 Outlook : Raising the mid-point of 2022 total revenue guidance to $3.65B driven by increases in the guidance mid...